These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 6820039)
41. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine]. Schiller B; Lysakowska E; Owczarska K Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849 [No Abstract] [Full Text] [Related]
42. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa]. Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310 [No Abstract] [Full Text] [Related]
43. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin]. Moroz AF; Kharitonova AM; Chanturiia TsK Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985 [TBL] [Abstract][Full Text] [Related]
44. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219 [TBL] [Abstract][Full Text] [Related]
45. Current status of Pseudomonas aeruginosa vaccine. Michelim L; Medeiros GS; Zavascki AP Curr Pharm Biotechnol; 2013; 14(11):951-9. PubMed ID: 24372247 [TBL] [Abstract][Full Text] [Related]
46. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa. Cachia PJ; Hodges RS Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116 [TBL] [Abstract][Full Text] [Related]
47. Effect of carbenicillin, gentamicin and vaccines on rats experimentally burned and infected with Pseudomonas aeruginosa. Toama MA; Hamed IM; Ashour SM Pharmazie; 1980; 35(4):228-30. PubMed ID: 6773076 [TBL] [Abstract][Full Text] [Related]
48. [Pseudomonas aeruginosa mucosus strain isolated from a patient with chronic bronchitis and a trial in autoimmunization]. Okano H; Honma Y; Shionoya H Kansenshogaku Zasshi; 1970 Oct; 44(7):380-7. PubMed ID: 4991749 [No Abstract] [Full Text] [Related]
49. [Immunoprophylaxis and immunotherapy of infection caused by Pseudomonas aeruginosa: research results and prospects]. Stanislavskiĭ ES; Joó I Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):22-31. PubMed ID: 6414198 [No Abstract] [Full Text] [Related]
50. Pseudomonas immunoglobulin and vaccine in burn patients. Bose B Lancet; 1981 Feb; 1(8217):435. PubMed ID: 6110056 [No Abstract] [Full Text] [Related]
51. [Prophylactic effects of Pseudomonas aeruginosa vaccine on patients with chronic pulmonary disease]. Tateda K; Yamaguchi K Nihon Rinsho; 1991 Oct; 49(10):2416-20. PubMed ID: 1749098 [No Abstract] [Full Text] [Related]
52. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection. Okada K; Kawaharajo K; Kasai T; Homma JY Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131 [TBL] [Abstract][Full Text] [Related]
53. Pseudomonas aeruginosa. Vaccines and immunotherapy. Pennington JE Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838 [TBL] [Abstract][Full Text] [Related]